It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
It is very uncertain whether esomeprazole changes withdrawals due to adverse events at 8 weeks compared with fluticasone (very low certainty).
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events at 12 weeks compared with four‐food elimination diet (very low certainty).
Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).